Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics, announced it will present and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference scheduled for May 20-21, 2026. The company’s presentation is set to begin at 3:15 p.m. ET on May 21, 2026, with additional virtual one-on-one investor meetings planned throughout the conference.
This presentation provides Oragenics with a platform to update investors on its progress, particularly regarding its lead candidate ONP-002, a potential first-in-class treatment for concussion and mild traumatic brain injury (mTBI). The company is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The intranasal delivery platform developed by Oragenics has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.
The Sidoti conference is a key event for micro-cap companies to connect with investors, and Oragenics’ participation underscores its commitment to advancing its pipeline and engaging with the investment community. The company’s presentation will likely detail its clinical development strategy, including timelines for upcoming trials and potential milestones.
For more information about Oragenics and its pipeline, visit the company’s website at oragenics.com. The full press release is available at https://ibn.fm/MLd0Y. Investors seeking the latest news and updates can access the company’s newsroom at https://ibn.fm/OGEN.
Oragenics is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company is committed to developing innovative therapies that address significant unmet medical needs in neurological care. Its intranasal delivery platform offers a non-invasive approach that may improve drug delivery to the brain, potentially enhancing efficacy and patient compliance.
The announcement of Oragenics’ participation in the Sidoti conference is significant as it provides an opportunity for the company to gain visibility among investors and potentially attract funding to support its clinical development programs. With the global burden of traumatic brain injury and neurodegenerative diseases, Oragenics’ focus on neurological therapeutics addresses a critical healthcare need.
